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57 ABSTRACT 
Biocompatible microcapsules useful for transplanting 
foreign material into an animal body, and the method of 
their production, are described, wherein the microcap 
Sules contain an outermost layer of water soluble non 
ionic polymers such as PEO to create resistance to cell 
adhesion on the surface of the microcapsules. 
11 Claims, 13 Drawing Sheets 
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This is a divisional of co-pending application Ser. No. 
07/598,880, filed on Oct. 5, 1990. 
BACKGROUND 
Microencapsulation of materials for transport to and 
/or growth within an animal is an area of research cur 
rently attracting much interest. The use of microcap 
sules provides the potential for such medically impor 
tant procedures as treatment of insulin-dependent diabe 
tes mellitus (IDDM) in humans through transplantation 
of insulin-producing cells, and timed release or long 
term delivery of drugs to an animal. 
The microencapsulation membrane plays a critical 
role in the treatment of IDDM by microencapsulated 
islet cells, as well as treatment of other diseases with 
other encapsulated material. Not only must it prohibit 
proteins of the immune system from entering the cap 
sule, but it must also interact with the host tissues in a 
biocompatible way. In this sense, biocompatibility 
means that the membrane will not initiate an inflamma 
tory response and that it will not support cell adhesion 
and stimulate overgrowth. If overgrowth occurs, the 
oxygen and nutrient supply to the islets will be limited 
and they will die. The area of biocompatibility of micro 
capsules, however, has received relatively little atten 
tion. 
The principle of immunoisolation is to surround the 
cells with a biocompatible semipermeable membrane, 
which allows free diffusion of nutrients, messenger 
compounds, cell wastes, and cell products, while isolat 
ing the cells from the host's immune system. The cells 
may be individual or clumped in tissue, Messenger com 
pounds and cell products include glucose, Cat, and 
insulin. 
Two methods for the immunoisolation of cells exists: 
hollow-fiber devices and microencapsulation. One form 
of hollow-fiber devices are an artificial capillary system 
consisting of hollow fibers to which cells are seeded on 
their exteriors, and which are enclosed in a rigid cham 
ber that is connected to the recipient as a vascular shunt. 
Early devices using insulin producing cells reversed 
diabetes for limited periods with high doses of heparin. 
Sun et al. (1977) Diabetes, 26:1136-39. But even with 
heparin, blood clot formation was a major problem. To 
reduce the formation of clots, which suffocated the 
cells, Altman et al. have seeded Amicon fibers success 
fully, with nearly half of the animal recipients having 
normal blood glucose levels for over a year. Altman et 
al. (1986) Diabetes, 35:625-33. However, the Amicon 
fibers are fragile and they have a limited surface area 
available for diffusion. A U-shaped ultrafiltration design 
developed by Reach et al. can solve the diffusion prob 
lem, but this design still suffers from the fragility of the 
Amicon fibers and from the formation of blood clots at 
the junction with the vascular system. Reach et al. 
(1984) Diabetes, 33:752-61. 
The transplantation of microencapsulated cells or 
tissue can overcome the hollow-fiber associated prob 
lens of diffusion limitations and vascular complications. 
Originally, Sun and Lim demonstrated the technique by 
encapsulating rat pancreatic islet cells into a membrane 
composed of layers of alginate, polyhysine, and polyeth 
yleneimine. Sun and Lim (1980) Science, 210:908-910. 














duced diabetic rats. These microcapsules corrected the 
diabetic state for only 2 to 3 weeks. 
Gradually the technique improved. A large improve 
ment was making the multi-layer membrane from algi 
nate-polylysinealginate, which is stronger and has con 
trollable permeability parameters. Goosen et al. (1985) 
Biotech. and Bioengin.., XXVII:146-50. King and 
Goosen et al. developed methods for decreasing the 
viscosity of the gel inside so that the tissue or cells are 
in a more natural environment (1987) Biotechnology 
Progress, 3:231-240. A further advance was making the 
microcapsules in a more uniform, smooth, spherical 
shape which improved their strength. Walter et al. 
Poster Group H. 
With these changes, Sun et al. have transplanted rat 
islets of Langerhans into chemically induced diabetic 
rats which have reversed the diabetic state for up to 780 
days, Sun (1987) Trans Am Soc. Artif. Intern Organs, 
XXXIII:787-790. In vitro studies have shown that anti 
bodies from Type 1 human diabetic patients were not 
able to suppress encapsulated cells, Darquy and Reach 
(1985) Diabetologia, 28:776-80. Therefore, it seems that 
microencapsulation can protect cells from antibodies. 
However, there are still several serious problems in 
regards to biocompatibility. Sun has reported finding 
fibroblast-like cells on the external surfaces of intact 
microcapsules. Sun had transplanted the microencapsu 
lated rat islet cells into diabetic rats. Sun (1987) Trans 
Am. Soc. Artif. Intern Organs XXXIII:787-790. In his 
articles, Sun has specifically recognized the need to 
improve the biocompatibility of the microcapsules. Id. 
at 810. 
Other published studies have also seen this inflamma 
tory response to transplanted microencapsulated cells. 
In another study of microencapsulated rat islet cells, 
O'Shea and Sun found that the microcapsules that they 
transplanted into chemically induced diabetic mice had 
cell overgrowth in the range of 0-10 layers of cells. The 
overgrowing cells included fibroblasts, macrophage 
like cells and neutrophils. There was also collagen 
around the capsules. O'Shea and Sun (1986) Diabetes, 
35:943–946. Again, O'Shea and Sun expressly recog 
nized that the biocompatibility of the microcapsules 
must be improved. Id. at 946. 
The inflammatory response is not limited to trans 
plants of islet cells. Wong and Chang have reported 
recovering clumped microcapsules of rat hepatocytes 
after they were transplanted into mice with liver failure. 
They found no viable cells within the clumped micro 
capsules, which were recovered only seven days after 
transplantation. Wong and Chang (1988) Biomat., Art. 
Cells, Art. Org., 16(4):731-739. The cells probably died 
because they were cut off from nutrients when the cells 
grew over the semi-permeable membrane. 
Current formulations for microcapsules result in al 
gin-polycationic polymer-algin composites. The ex 
terior of these membranes are negatively charged, due 
to the algin, and may have positive charges due to ex 
posed polycation; as such they support protein adsorp 
tion and cell attachment. In general, these microcap 
sules become overgrown with fibroblasts and other 
cells. This overgrowth has many negative effects, in 
cluding impairment of the functioning of the microcap 
sule by blocking permeability, and induction of immune 
response by the host animal. 
The microencapsulation technique that had previ 
ously met with the most success is that of O'Shea and 
Sun (1986) Diabetes, 35:943-946. Their method uses the 
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strong interaction between large multicharged mole 
cules, one cationic and one anionic, to form a very thin, 
stable, spherical membrane shell that resists the diffu 
sion of large proteins, such as antibodies, while allowing 
the diffusion of smaller proteins, such as insulin. 5 
Such a membrane is obtained by suspending cells to 
be encapsulated in a solution of algin, a polyanionic 
polysaccharide that is obtained from kelp. Very small 
droplets of this solution are formed, approximately 
0.1-1.0 mm in diameter depending on the size of the 10 
material to be encapsulated, and these droplets are 
gelled on contact with a fairly highly concentrated 
Solution of calcium chloride, 0.2-1.6% CaCl2. The cal 
cium cations, in this high concentration, serve to revers 
ibly crosslink the anionic polysaccharide chains, form- 15 
ing the gel. 
To obtain a membrane that would be stable at physio 
logic concentrations of calcium, the negatively charged 
microcapsule is placed in a solution of a positively 
charged polymer, for example, polylysine: The opposite 20 
charges interact, leading to very strong adsorption of 
the polylysine, resulting in a stable, strongly crosslinked 
surface, Similarly, an outer layer of algin is added, 
yielding an algin-polylysine-algin composite trilayer 
membrane. 25 
The solid inner core of gelled algin is liquefied by 
placing the microcapsules in a solution of sodium citrate 
to chelate the gelling calcium. At physiologic calcium 
levels, the core remains liquid and the algin, if of low 
enough molecular weight, diffuses out of the core. The 30 
result is a spherical shell of algin-polylysine-algin sur 
rounding the microencapsulated cells. 
It is predictable that such an algin-polylysine-algin 
microcapsule will not resist tissue overgrowth. The 
exterior surface is highly charged, with both positive 35 
and negative charges, and would thus be expected to 
adsorb significant amounts of protein and to support 
cell adhesion. Andrade et al. (1986) Adv. Polymer Sci., 
79:1-63. Experimentally, tissue overgrowth has been 
observed to be the point of failure of the microencapsu- 40 
lation therapy. O'Shea and Sun (1986). 
Poly(ethyleneoxide) (PEO) has been used in numer 
ous instances to decrease cellular attachment. For in 
stance. PEO coatings on PVC tubes have been reported 
as significantly reducing platelet adhesion in vitro and 45 
preventing adhesion and thrombus formation in 72 day 
PVC tube implants in vivo. (Y. Moriet. al., Trans. Am. 
Soc. Artif. Intern. Organs 28:459 (1982)). Volume re 
striction and osmotic repulsion effects were credited 
with producing the low adsorption of blood constitu- 50 
ents. (Id.). Later research concluded that there were 
micro flows of water induced by the cilia-like move 
ments of hydrated PEO chains which prevent plasma 
proteins from absorbing onto the surface of coated PVC 
tubes. (S. Nagaoka and A. Nakao, Biomaterials li:l 1955 
(1990)). 
In addition to PVC tube coatings, others have re 
ported that segmented polyurethanes containing PEO 
as the soft segment, when cast as films or coatings, show 
reduced platelet retention in vitro. (E. W. Merrill et al., 60 
Trans. Am. Soc. Artif. Intern. Organs 28:482 (1982)). 
PEG-polyurethane coatings on disks made of Pelle 
thane were shown to cause the disks to have reduced 
cellular adhesion for up to 3 months when implanted 
into the peritoneal cavities of mice. (S. K. Hunter et al., 65 
Trans. Am. Soc. Artif. Intern. Organs 29:250 (1983)). 
Block co-polymers consisting of poly(N-acetyle 
thyleneimine) and PEO, when coated on solids such as 
4. 
glass beads or silica, were found to increase the homeo 
compatibility of the solids by decreasing adsorption of 
hydrophilic macromolecules. (C. Maechling-Strasser et 
al., J. of Biomedical Materials Research 23: 1385 (1989)). 
Long term canine vascular implants of Biomer coated 
with polymers have been tested for adsorption of prote 
ins. (C. Nojiri et al. Trans. Am. So. Artif. Intern. Or 
gans, 35:357 (1989)). The polymer coatings found to 
have "excellent non-thrombogenic performance" were: 
1) Heparin immobilized on Biomer using a long chain 
PEO spacer; and 2) a block copolymer composed of 
2-hydroxyethyl methacrylate (HEMA) and styrene. 
(Id.). 
Low density polyethylene (a hydrophobic polymer 
surface) coated with a block copolymer containing 
water insoluble components (such as polypropylene 
oxide or polybutylene oxide) and PEO components 
(water soluble components) was shown to have protein 
resistant properties. (J. H. Lee et al., J. of Biomedical 
Materials Research, 23:351 (1989)). The surface was 
created by a simple coating process where the hydro 
phobic components of the polymer adsorbed on the 
hydrophobic surface of the polyethylene from an aque 
ous solution, the PEO chains were then at least partially 
extended into the aqueous solution creating a protein 
resistant surface. (Id.). 
Processes used to achieve PEO surfaces other than a 
simple coating process have been described: block co 
polymerization (Y. Mori supra); incorporation into 
polyurethanes (E. W. Merrill supra); and direct attach 
ment of PEO molecules to the cyanuric chloride acti 
vated surface of a poly(ethylene terephthalate) film. (W. 
R. Gombotz et al., J. of Applied Polymer Science 37.91 
(1989)). 
Most of the foregoing uses of PEO have been on 
concave or flat surfaces; they have not been on small 
convex surfaces such as are found with microcapsules. 
Due to the fact that the non-ionic water soluble poly 
mers face outward from the microcapsule, it could not 
be predicted from the prior art that PEO and other 
non-ionic water soluble polymers could form a suffi 
cient barrier to protect microcapsular surfaces. Like 
wise, the chemistry was not known for attaching suffi 
cient quantities of water soluble non-ionic polymers to 
the outer surfaces of microcapsules to create this bar 
le. 
SUMMARY OF THE INVENTION 
This invention for the first time demonstrates the use 
of water soluble non-ionic polymers such as PEO to 
create resistance to cell adhesion on the surface of mi 
crocapsules. 
This invention provides a method for transplanting 
foreign material into an animal body in a biocompatible 
manner. This is accomplished by providing microcap 
sules, biocomatible with the recipient animal, capable 
of encapsulating the foreign material to be transplanted 
into that animal. The normally charged outer layer of 
the microcapsules is covered by water soluble non-ionic 
polymers such as poly(ethylene oxide) (PEO) which act 
to shield the charge. These polymers are grafted to the 
polycationic polymers, such as poly-L-lysine (PLL) 
molecules used as at least one of the layers of the micro 
capsule, such that they create a non-ionic barrier be 
tween the outer layer of the microcapsule (made of 
essentially either polycationic polymers, such as PLL. 
or polyanionic polymers, such as aginate) and the re 
cipient animal. The microcapsules then appear, from the 
5,232,984 
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outside, to have water-like surface properties, thus re 
ducing the driving force for protein adsorption. Fur 
ther, the surface, at the macromolecular level, is in a 
high degree of motion, further reducing protein adsorp 
tion and cell attachment. 
This invention further provides microcapsules, and a 
method for their production, in which the surface is 
more resistant to cell adhesion. As a result, overgrowth 
of the microcapsules by cells such as fibroblasts and 
macrophages is severely decreased or eliminated. Cells 
contained within the microcapsules are able to continue 
to receive nutrients and signal molecules, and produce 
whatever is their desired product. Any product present 
in the microcapsules, such as insulin produced by islet 
cells, can continue to diffuse out of the microcapsules 
and be available for utilization by the host animal. 
This invention also provides microcapsules, and a 
method for their production, which will not apprecia 
bly stimulate immune response or cytokine release by 
the recipient animal. Thus, these microcapsules can be 
transplanted to a recipient animal and function there 
with minimal interference from that animal's immune 
system. 
This invention provides microcapsules with variable 
levels of permeability. This is accomplished by using 
varying numbers of layers to make the microcapsules, 
with an increased number of layers decreasing the pore 
size. Thus, the microcapsules can be created to meet a 
particular need for large or small pores and the resulting 
level of permeability. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the effect of the molecular weight of 
the water soluble non-ionic polymer on permeability of 
microspheres formed using grafted material. 
FIG. 2 shows the effect of the number of layers used 
to form the microspheres on permeability. 
FIG. 3 is a schematic of the activation reaction using 
carbodiimidazole. 
FIG. 4 is a schematic of the activation reaction using 
sulfonyl chlorides, where R is as shown. 
FIGS. 5A, 5B and 5C are schematic of the activation 
reaction using chlorocarbonates. 
FIG. 5A shows the reaction using 4-nitrophenyl 
chloroformate, FIG. 5B uses N-hydroxysuccinyl chlo 
roformate, and FIG. 5C uses 2,3,5-trichlorophenyl 
chloroformate. 
FIGS. 6A, 6B and 6C show cell counts obtained from 
peritoneal lavage after implantation of microcapsules. 
CDI (carbodiimidazole), PFBS (pentafluoroben 
zenesulfonyl chloride), trifyl (trifyl chloride), and chlo 
rocarb (chlorocarbonate) were used to activate PEO 
(poly(ethylene oxide)) for grafting to poly(1-lysine) 
according to this invention. FIG. 6A represents results 
when PEO of molecular weight around 5kd was used; 
FIG. 6B used PEO of 10kd; and FIG. 6C shows results 
from PEO of 18.5kd. Numbers of cells are shown on the 
left of each graft. e--7 stands for 107, so that 1.00e--7 is 
1.00X 107 cells. 
FIGS. 7A and 7B show growth of cells on micro 
spheres made by the standard procedures available 
prior to this invention, using ungrafted poly(1-lysine). 
FIG. 7A is 40X phase contrast magnification of micro 
spheres, while FIG. 7B is 400X. 
FIGS. 8A, 8B and 8C show microspheres made with 
poly(ethylene oxide) (PEO) activated by car 
bodiimidazole and grafted to poly(1-lysine) (PLL) to 












FIG. 8B the PEO was 10 kid, and in FIG. 8C the PEO 
was 18.5 k.d. These figures show the whole micro 
spheres magnified 40X. 
FIGS. 9A,9B, 9C,9D,9E and 9F show microspheres 
made with PEO activated by trifyl chloride and grafted 
to PLL to create PEO-g-PLL. In FIGS. 9A and 9B, 5 
kid PEO was used. In FIGS. 9C and 9D, the PEO was 
10 kd, and in FIGS. 9E and 9F the PEO was 18.5 kid. 
FIGS. 9A, 9C and 9E show whole microspheres, pho 
tographed at 40X, while FIGS. 9B, 9D and 9F show 
400X magnified surfaces of the microspheres. 
FIGS. 10A, 10B and 10C show microspheres made 
with PEO activated by pentafluorobenzenesulfonyl 
chloride (PFBS) and grafted to PLL to create PEO-g- 
PLL. In FIG. 10A 5 k.d PEO was used; in FIG. 10B the 
PEO was 10 kid, and in FIG. 10C the PEO was 18.5 kid. 
These figures show the whole microspheres magnified 
40X. 
FIG. 11A, 11B, 11C, 11D, 11E, and 11F show micro 
spheres made with PEO activated by chlorocarbonate 
and grafted to PLL to create PEO-g-PLL. In FIGS. 
11A and 11B, 5 k.d PEO was used. In FIGS. 11C and 
11D, the PEO was 10 kid, and in FIGS. 11E and 11F the 
PEO was 18.5 kid. FIGS. 11A, 11C and 11E show 
whole microspheres magnified 40X, while FIGS. 11B, 
11D and 11F show surfaces of the microspheres magni 
fied 400X. 
DETAILED DESCRIPTION 
According to this invention, microcapsules are as 
sembled from various layers of a polyanionic polysac 
charide, such as alginate, and a polycationic polymer, 
such as poly(1-lysine) (PLL). The polycationic polymer 
need not be a polypeptide. The outer polycation layer is 
composed of the polycationic polymer grafted to a 
water soluble non-ionic polymer, such as poly(ethylene 
oxide) (PEO) to form a graft copolymer, such as PLL 
g-PEO. The layers are alternated such that the oppo 
sitely charged polymers, for example algin and PLL, 
aggregate to form coacervates, such as algin-PLL 
-algin. This creates an ionically crosslinked mem 
brane. 
However, PLL is known to promote cell adhesion, so 
at least the outermost layer of PLL or other polycation 
in this invention is composed of the graft copolymer. 
PEO, as well as other water soluble non-ionic polymers, 
have been shown to reduce cell adhesion when used to 
modify a surface. Lee et al. (1989) J. Biomed. Materials 
Res. 23:351-368. This dual-character graft copolymer 
interacts with the polyanionic layer, such as algin, to 
form a stable membrane through interactions between 
the polycationic backbone, such as PLL, and the poly 
anionic layer. The long arms of the non-ionic polymer, 
such as PEO, however, serve to obscure the charged 
layers from the tissues, thereby improving the biocom 
patibility. They create a very hydrophilic and un 
charged layer, to which very little, if any, protein or 
cells adhere. 
The water soluble non-ionic polymers are covalently 
attached to the polycationic polymers and point in all 
directions including outward from the microcapsule. 
1. Water Soluble Non-ionic Polymers 
Water soluble non-ionic polymers with molecular 
weights of between 2000 and 50,000 are suitable for this 
procedure. PEO of approximately 10,000 m.w.. is the 
most preferred. Molecules with molecular weights 
lower than around 2000 do not adequately shield the 
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microcapsule, while those greater than around 50,000 
create steric limitations on the microcapsules. In addi 
tion, molecules with higher molecular weights cause an 
increase in the swelling of the microcapsules, interfer 
ing with the interactions between the polyanionic poly 
Saccharides and the polycationic polypeptides. As a 
result, the polyanionic polysaccharide layer does not 
adhere as well, and the integrity of the microcapsules 
can be threatened. 
Additionally, the size of the water soluble non-ionic 
polymers affects permeability of the microcapsule. The 
larger molecules create greater permeability. This fea 
ture can be manipulated to obtain the optimal degree of 
permeability for the particular use of the microcapsules. 
For microcapsules encapsulating insulin-producing islet 
cells, the optimal permeability is created with PEO 
around 10,000 m.w.. in a pentalayer membrane (see 
below and FIGS. 1 and 2). 
2. Activation 
Procedures used to graft the water soluble non-ionic 
polymers to the polycationic polymers include but are 
not limited to use of carbodiimidazole, sulfonyl chlo 
rides, or chlorocarbonates to activate the water soluble 
non-ionic polymers. These reagents are used to activate 
free hydroxyl groups for coupling to polycationic poly 
peptides. 
Other chemistries for linking water soluble non-ionic 
polymers to polycationic polymers, known by those 
skilled in the art, can also be used. 
a. Carbodiimidazole 
To X millimoles of PEO or other water soluble non 
ionic polymer in at least a 1% solution in anhydrous 
acetone or other anhydrous organic solvent is added at 
least IX, preferably 5X millinoles of carbodiimidazole. 
Larger quantities of carbodiimidazole can be used but 
will not increase the rate or amount of the activation. 
The reaction mixture is stirred at a temperature above 
the freezing point and below the melting point of the 
mixture, preferably at room temperature of around 22 
C., for at least hour, preferably around 2 hours. The 
product is then washed at least twice with methanol 
with HCl or other strong acid to convert the organic 
base to the conjugate, and finally with pure methanol. 
Washes can be formed by solubilization of the reaction 
product in the wash solvent, followed by reprecipita 
tion and sedimentation, for example by settling at 1 g or 
in a centrifuge at higher acceleration, preferably 1000 
Tcf for 10 minutes. The final wash is checked to be free 
of any residual pyridine or other base by UV spectro 
photometry. The pelleted product is then recovered. 
Other purification schemes known by those skilled in 
the art can also be used. The product can then be lyoph 
ilized and stored. FIG. 1 shows the reaction scheme. 
b. Sulfonyl chlorides 
To create good leaving group characteristics in sulfo 
nyl chlorides, two main approaches are used: the first is 
fluorination and the second is nitration. Thus a number 
of organic chlorides can be used to produce end 
activated water soluble non-ionic polymer chains with a 
varying degree of effectiveness. By way of example, the 
order of reactivity of coupling for Toluene sulfonyl 
chloride (Tosyl chloride):Trifluoroethanesulfonyl chlo 
ride (Tresyl chloride):Trifluoromethanesulfonyl chlo 
ride (Trify) chloride) is 1:100:4000. As reactivity in 








ride with intermediate traits is preferred. Other sulfonyl 
chlorides such as dansyl, dipsyl, and diabsy chloride 
can also be used, but with lower effectiveness. Other 
problems such as difficulty in removal of unreacted 
dansyl functions by nucleophiles and tendency for diab 
syl chloride to undergo further secondary reactions 
leading to a significant red shift make these sulfonyl 
chlorides less suitable. These may be overcome, for 
example, by employing higher levels of the activating 
agent and subsequently purifying the products of the 
primary reaction from the products of the secondary 
competing reactions. 
Another compound, Pentafluorobenzenesulfonyl 
chloride (PFBS), however, is as reactive as tresyl chlo 
ride, is cheaper, and is chromophoric, thus allowing an 
easy quantification of the extent of the reaction. Thus 
PFBS is a preferred reagent in this group. 
Sulfonyl chlorides are readily available from a num 
ber of commercial chemical suppliers such as Aldrich 
and Fluka. 
To X millimoles of PEO or other nonionic water 
soluble polymer in at least a 1% solution in anhydrous 
methylene chloride or other anhydrous organic solvent 
at a temperature above the freezing point and below the 
melting point of the mixture, preferably 4 C., is added 
at least IX, preferably 5X millinoles of sulfonyl chlo 
ride (larger quantities can be used but will not increase 
the rate or amount of the activation) and approximately 
twice as much pyridine, triethylamine, or other organic 
aprotic base, as sulfonyl chloride. The reaction mixture 
is stirred for at least 10 minutes, preferably around 2 
hours. The product is then washed at least twice with 
methanol with HCl or other strong acid to convert the 
organic base to the conjugate, and finally with pure 
methanol, Washes can be formed by solubilization of 
the reaction product in the wash solvent, followed by 
reprecipitation and sedimentation, for example by set 
tling at 1 g or in a centrifuge at higher acceleration, 
preferably 1000 rcf for 10 minutes. The final wash is 
checked to be free of any residual pyridine or other base 
by UV spectrophotometry. The pelleted product is then 
recovered. Other purification schemes known by those 
skilled in the art can also be used. The product can then 
be lyophilized and stored. FIG. 2 shows the reaction 
scheme. 
c. Chlorocarbonates 
Chlorocarbonates such as P-nitrophenyl chlorocar 
bonate (Fluka), 2,4,5 trichlorophenyl chlorocarbonate, 
and N-hydroxysuccinanide chlorocarbonate are exam 
ples that react efficiently for activation of hydroxyl 
containing compounds such as the water soluble non 
ionic polymers used in this invention. Other chlorocar 
bonates known by those skilled in the art can also be 
used. 
To X millimoles of PEO or other water soluble non 
ionic polymer in at least a 1% solution in anhydrous 
methylene chloride or other anhydrous organic solvent 
at a temperature above the freezing point and below the 
melting point of the mixture, preferably 4 C., is added 
at least IX, preferably 5X millimoles of chlorocarbonate 
(larger quantities can be used but will not increase the 
rate or amount of the activation) and approximately 
twice as much pyridine, triethyl amine or other organic 
aprotic base. The reaction mixture is stirred at a temper 
ature above the freezing point and below the melting 
point of the mixture, preferably at room temperature of 
around 22 C., for at least 10 minutes, preferably around 
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2 hours. The product is then washed at least twice with 
methanol with HCl or other strong acid to convert the 
organic base to the conjugate, and finally with pure 
methanol. Washes can be performed by solubilization of 
the reaction product in the wash solvent, followed by 
reprecipitation and sedimentation, for example by set 
tling at 1 g or in a centrifuge at higher acceleration, 
preferably 1000 rcf for 10 minutes. The final wash is 
checked to be free of an residual pyridine or other base 
by UV spectrophotometry. The pelleted product is then 
recovered. Other purification schemes known by those 
skilled in the art can also be used. The product can then 
be lyophilized and stored. FIG. 3 shows the reaction 
schemes. 
3. Polycationic Polymers 
Polycationic polymers are selected for their ability to 
form strong membrane coacervates with algin or other 
polyanions. Such polycationic polymers include poly 
peptides and non-polypeptides. Polypeptides include, 
but are not limited to, polylysine and polyornithine. 
Non-polypeptides include, but are not limited to, poly 
ethyleneimine and polyallylamine. The molecular 
weight of these polycationic polymers is important but 
not critical, and optimal values are determined by their 
ability to form strong membrane coacervates. Very low 
molecular weight polycation polymers generally form 
membranes that are weak and very high polycation 
polymers generally form membrane coacervates that 
are very thin. Typical values for the molecular weight 
of the polycation polymers are between about 10,000 
and 75,000. A preferred substrate is poly(1-lysine), 
which has been previously used in its ungrafted form as 
a component of microcapsule membranes. 
4. Coupling 
Activated water soluble non-ionic polymers are next 
coupled to the polycationic polymers. The polymers are 
mixed into a solution of the activated PEO or other 
water soluble nonionic polymer, agitated and allowed 
to react for a period of at least day. The pH of the 
solution is maintained around 9-2. The coupling reac 
tion is stopped by quenching through the addition of an 
amine or a thiol such as mercaptoethanol. Quenching is 
allowed to proceed for at least hour, preferably 10 
hours. 
If desired, ultrafiltration, dialysis, or Soxlet extraction 
can be used to separate the unreacted PEO from the 
PLL-g-PEO. In addition, the extent of reaction can be 
estimated using a spectrophotometric titration of amine 
groups where, for example, the amine groups are re 
acted with 2,4,6-trinitrobenzene sulfonic acid, forming a 
product that absorbs at 440 nm. The extent of reaction 
can also be determined by estimating the relative 
amounts of copolymers using H-NMR. 
5. Formation of Microcapsules 
Formation of the microcapsule is by standard tech 
niques. O'Shea and Sun (1986). Material to be encapsu 
lated is suspended in a solution of polyanionic polysac 
charides, preferably algin, at a concentration that will 
allow the cells to receive adequate nutrients as well as 
signal molecules and produce the desired product(s) 
once the microcapsules are formed. A preferred con 
centration is lx 10 to 1 x 108 a cells/ml Droplets of this 
solution are dropped into a solution of isotonic calcium 
chloride in saline, preferably 0.2 to 1.6% CaCl2.2H2O. 













gauge needle or orifice in a sterile air stream is one 
method of producing the droplets. They are then 
washed, in isotonic saline or buffer and placed in a 
solution of the polycationic polymer, preferably PLL. 
Alternatively, they can be placed in a solution of water 
soluble non-ionic polymer-grafted-polycationic poly 
mer, as described herein. The polycationic polymer or 
water soluble non-ionic polymer-grafted-polycationic 
polymer solution should be approximately 0.03%-0.3%, 
preferably 0.1%. The droplets are allowed to react with 
the polymers for a period of time from 3-30 minutes, 
preferably 12 minutes. 
The microcapsules are removed from the polymer 
solution by, for example, decanting the liquid. The 2 
layer droplets are then washed with isotonic saline or 
buffer and may be coated with one or more layer of 
polyanionic polysaccharides, preferably another layer 
of algin. This is accomplished by reacting the bilayer 
droplets with a 0.05-0.25% solution of polyanionic 
polysaccharide, preferably a 0.15% solution of algin, 
for a period of 3-30 minutes, preferably 8 minutes. 
Next, a layer of water soluble non-ionic polymer 
grafted-polycationic polymer, preferably PEO-g-PLL, 
can be added to the microcapsule. This is performed by 
incubation of the microcapsules in a solution of the 
grafted polymer at the same concentration range, for 
the same period of time, as for the non-grafted polyca 
tionic polymers. Alternatively, the first layer of polyca 
tionic polymer may be replaced by water soluble non 
ionic polymer-grafted-polycationic polymer, such as 
PLL-g-PEO, and the second layer of this grafted-poly 
cationic polymer may be included or omitted. An outer 
layer of algin may or may not be added at the same 
concentration range, for the same period of time, as for 
the inner one. 
The number of layers used in each microcapsule can 
be used to determine several parameters of interest for 
transplantation. The prior art discloses use of microcap 
sules with 3 layers, as described in O'Shea and Sun 
(1986). The number of layers can be increased by add 
ing subsequent alternating layers of polyanionic poly 
saccharides and polycationic polypeptides. The polyca 
tionic polymers grafted to the water soluble non-ionic 
polymers should at least be used as the last or next to 
last layer of the microcapsule, and must be at least the 
outermost polycationic layer. 
Increasing the number of layers decreases the perme 
ability of the microcapsules. Thus, permeability can be 
controlled to selectively allow diffusion across the mi 
crocapsule membrane. The addition of water soluble 
non-ionic polymers to the polycationic polypeptide 
layer increases permeability. Therefore, in order to 
eliminate the immune response of the host animal to 
cells encapsulated within these microcapsules, such as 
xenograft insulin producing islet cells, it is necessary to 
counter this permeability increase. A preferred method 
is to add an additional two layers to the surface of the 
microcapsule. This brings the permeability back to the 
level found in 3-layer microcapsules described in the art 
which do not have the grafted water soluble non-ionic 
polymers. 
Additionally, increasing the number of layers of the 
microcapsule membrane increases the strength and sta 
bility of the microcapsules. However, this stability must 
be balanced with the decrease in permeability caused by 
the increased layers. Thus, for use in encapsulating 
living cells that produce a desired product when trans 
planted to a host animal, a 5-layer microcapsule accord 
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ing to this invention is most preferred, whether made 
with both ungrafted and grafted polycation polymer or 
solely with grafted polycation polymer. 
Microcapsules formed by the above procedures can 
be degelled at this step to remove excess gelled polyan 
ionic polysaccharide immediately surrounding the en 
capsulated material. However, this procedure is not a 
necessary step, and the microcapsules will function well 
without degelling. If degelling is desired, standard pro 
cedures described in the art, such as incubation in a 
sodium citrate solution can be employed. O'Shea and 
Sun (1986). 
6. Implantation of Microcapsules 
Microcapsules are suspended in a solution compatible 
for injection, such as isotonic saline, buffer or tissue 
culture medium. Microcapsules can be implanted in the 
peritoneal cavity of a host animal by standard tech 
niques. In addition, they can be implanted in any bodily 
location which provides sufficient circulation of the 
products of the encapsulated material to allow meta 
bolic functioning of those products. For example, with 
microcapsules containing insulin-producing islet cells, 
intramuscular locations will allow sufficient exposure to 
the blood circulatory system to allow effective use of 
the insulin. 
EXAMPLE 
Activation of PEO Using Carbodiimidazole 
Three separate reactions were performed, each using 
PEO of a different molecular weight class. 1 millimole 
each of PEO-5K (5000 d), PEO-10K (10,000 d) and 
PEO-18.5K (18,500 d) were used. The PEO-5K mate 
rial was monomethoxy end terminated; as such these 
polymers had only one terminal, activatable hydroxyl 
group, thus minimizing cross-linking reactions in the 
coupling step. 50% solutions of these polymers were 
made up in anhydrous acetone which had been dried 
overnight over 4. A molecular sieves, and 5 millimoles 
of carbodiimidazole (CDI) was added to them. The 
reaction mixes were stirred at room temperature for 2 
hrs. The reaction mixes were then washed four times 
with 60 ml of anhydrous acetone by chilling the solution 
to 0 C. to precipitate, decanting, adding fresh solvent, 
and warming to 22 C. to redissolve. The product was 
then lyophilized and stored. 
EXAMPLE 2 
Activation of PEO Using Sulfonyl Chlorides 
Three separate reactions were performed, each using 
PEO of a different molecular weight class. 1 millinole 
each of PEO-5K, PEO-1OK AND PEO-18.5K were 
used. The PEO-5K material was mononethoxy end 
terminated; as such these polymers had only one termi 
nai, activatable hydroxyl group, thus minimizing cross 
linking reactions in the coupling step. 50% weight 
/volume solutions of these polymers were made up in 
anhydrpus acetone which had been dried overnight 
over 4. A molecular sieves. The solutions were cooled to 
4 C. and 5 millinoles of trify) chloride or PFBS was 
added to these solutions along with 10 millinoles of 
pyridine. The reaction mix was stirred mechanically at 
room temperature for 2 hrs., at the end of which it was 
washed twice with 60 ml each of methanol containing 
0.2 ml concentrated HCl, three times with 60 m each of 
methanol containing 50 ul of HCl, and finally with pure 
methanol. The washes were done by solubilization at 













tion at 1000 rcf. The final wash was checked to be free 
of any residual pyridine by ultraviolet spectroscopy. 
The product was lyophilized and stored at 4 C. 
EXAMPLE 3 
Activation of PEO Using p-Nitrophenyl 
Chlorocarbonate 
Three separate reactions were performed, each using 
PEO of a different molecular weight class. 1 millimole 
each of PEO-5K, PEO-OK AND PEO-18.5K were 
used. The PEO-5K material was monomethoxy end 
terminated; as such these polymers had only one termi 
nal, activatable hydroxyl group, thus minimizing cross 
linking reactions in the coupling step. 50% solutions of 
these polymers were made up in acetone Which had 
been dried overnight over 4. A molecular sieves. The 
solutions were then cooled to 4 C. and 5 millimoles 
each of pyridine and triethylamine and 5 millimoles of 
p-nitrophenyl chlorocarbonate (chlorocarb) were 
added. The mixtures were mechanically stirred and the 
reaction was allowed to proceed at room temperature 
for 2 hrs. The reaction mix was then washed with cold 
acetone by adding 60 ml acetone at room temperature, 
cooling to 4 C. and centrifuging at 1000 rcf. The wash 
ing was repeated once with acetone, then with a 5% 
acetic acid solution in dioxane, and finally with metha 
nol. The product was lyophilized and stored. 
EXAMPLE 4 
Coupling Activated PEO to PLL 
20 mg of Poly(1-lysine) (PLL), molecular weight 
around 17,000, was added to each 50% w/v solution of 
the above activated polymers in 500 mM sodium borate 
buffer (pH 9) for 24 hours. The coupling reaction was 
stopped by quenching using 0.36 mls of 14M Mercapto 
ethanol. The quenching was allowed to proceed for 10 
hrs. 
The PEO-5K grafted to PLL and PEO-10K grafted 
to PLL formed clear solutions. On the other hand, the 
PEO-18.5K grafted to PLL resulted in the formation of 
a very high molecular weight macromolecular network 
which had the consistency of a gel. Some parts of this 
gel were soluble when diluted further but some cross 
linked portions remained insoluble. 
No attempt was made to separate the unreacted PEO 
from the PLL-g-PEO. The extent of reaction was esti 
mated using spectrophotometric titration of amine 
groups where the amine groups were reacted with 
2,4,6-trinitrobenzene sulfonic acid, forming a product 
that absorbs at 440 nm. 
EXAMPLE 5 
Relationship of Molecular Weight of the Water Soluble 
Non-Ionic Polymer to Permeability of Microspheres 
Use of grafted water soluble non-ionic polymer to 
polycationic polymer was found to affect the permeabil 
ity of microcapsules. Microspheres were formed using 
PEO of varying molecular weights grafted to PLL as 
the outer layer of a bilayer microsphere. The relation 
ship of the size of the PEO used to the permeability of 
the microspheres was investigated. 
5 ml of algin solution was mixed with 100 ul of 125I 
labelled BSA for microsphere fabrication. Micro 
spheres were formed following standard procedures. 
PLL-g-PEO having PEO chains of 5,000d, 10,000d, and 
100,000d were used as the outer layer. Control spheres 
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were formed having ungrafted PLL as the outer layer. 
The microspheres were degelled with citrate. The de 
gelled microspheres were incubated in 10 ml of citrate 
solution, which was sampled periodically for presence 
of I albumin that had secreted through the mem 
brane. For this sampling, 1 ml aliquots were counted in 
a gamma Scintillation counter. As can be seen in FIG. 1, 
permeability of the microspheres increased in direct 
proportion to the size of the PEO component of the 
outer layer, with control spheres having ungrafted PLL 
being the least permeable. 
The effects of the presence of PEO on permeability 
could be reversed by increasing the number of layers 
used to form the microspheres. Following standard 
procedures, microspheres were formed having from 
two to four layers. As can be seen in FIG. 2, microcap 
sules with PEO having 4 layers, where the inner poly 
cationic layer was of ungrafted PLL, had the same 
permeability characteristics as the control microcap 
sules with 3 layers. Thus, varying the number of layers 
altered the permeability characteristics of the micro 
spheres, and increasing the number of layers, using an 
inner layer of ungrafted PLL. returned the microcap 




Approximately 0.5 ml of microcapsules were taken 
for each sample. The samples were washed 2 times in 10 
ml each of isotonic saline. After the final wash, each 
sample of microcapsules was suspended in 5 ml phos 
phate buffered saline (0.2M) pH 7.4 (PBS) and aliquoted 
into two equal parts. Duplicate animals, male Swiss 
Sprague-Dawley nice 16-20 weeks old were used for 
each composition. Implants were made intraperitone 
ally (i.p.) using a 15 gauge needle. Animals were under 
ether anaesthesia, Microcapsules having an outermost 
layer of PLL without the grafted water soluble non 
ionic polymers were used as controls. 
EXAMPLE 7 
Characterization of Implanted Microcapsules 
The implants were retrieved after one week using 
peritoneal lavage. 5 ml of PBS, containing 10 U/ml 
heparin, was injected with pressure using a 22 gauge 
needle. The microcapsules were recovered using a 
transfer pipette through a small hole made in the muscle 
flap over the peritoneal cavity. 
a) Cell Counts 
An immediate count of free cells recovered in the 
fluid in conjunction with the microcapsules was taken. 
These cells were incubated in polystyrene petri dishes 
for 2 hrs and then washed and fixed in 2% glutaralde 
hyde. Those cells adhering to the petri dish were nearly 
uniformly found to be macrophages as revealed using a 
monoclonal antibody and secondary fluorescence tech 
nique. The primary antibody was a rat anti-mouse mac 
rophage antibody, clone #M1-70.15 from Sera-lab ob 
tained from Accurate Chemicals. The secondary anti 
body was a fluorescein conjugated goat anti-rat IgG 
polyclonal antibody obtained from Accurate Chemical. 
After antibody treatment, the samples were viewed by 
fluorescence microscopy. Some of the directly recov 
ered peritoneal lavage fluid and some control microcap 













using the antibody fluorescence technique and were 
qualitatively judged to be about 50% macrophages. 
The results, shown in FIG. 4, show that the number 
of macrophages free floating in the peritoneal fluid was 
decreased by use of the products of this invention. This 
figure shows cell counts from the samples. As can be 
seen from this figure, use of the technology described in 
this invention lowers the number of macrophages and 
other cells induced by the presence of microcapsules in 
the peritoneal cavity. Evidence of some foreign body 
giant cell formation was seen in all samples that had 
cellular attachment. Varying levels of fluorescence was 
seen in some macrophages which might be an artifact of 
non-uniform staining or may reflect different levels of 
cellular activation. A few cells which were not macro 
phages were also seen but their numbers were small. 
The number of cells present in the peritoneal cavity 
was inversely correlated to the molecular weight of the 
grafted PEO. 
b) Photomicrographs 
FIGS. 5 through 9 show a number of photomicro 
graphs of the recovered microcapsules. Photographs 
for each type of microcapsule were taken through a 
40X phase contrast and a 400X Hoffman optics micro 
scope. The lower magnification was used to reflect a 
broad cross-section of the microcapsules and the higher 
magnification was used to examine the surface of the 
microcapsules and closely examine cell attachment. 
The control microcapsules, shown in FIG. 5, showed 
heavy cellular overgrowth as expected. FIG. 5a shows 
a number of microspheres darkened by overgrowth of 
cells. FIG. 5b is a higher resolution version of FIG. 5a, 
showing individual cells on the surface. 
Microcapsules made according to the invention de 
scribed herein showed little or no cell attachment. This 
can be seen by the clarity and transparency of the mi 
crocapsular surfaces at the 40X magnification. Addi 
tionally, at 400X magnification, surfaces of the micro 
capsules made using trifyl chloride and chlorocarbonate 
technology show clean Surfaces. 
We claim: 
1. A method for grafting water soluble non-ionic 
polymers to polyamine or polyimine polycationic poly 
mers comprising: 
a) activating the reactive groups capable of being 
covalently linked to a coupling agent on the water 
soluble non-ionic polymers by using an activation 
agent selected from the group consisting of car 
bodiimidazole, sulfonyl chlorides and chlorocar 
bonates, and 
b) coupling the activated water soluble non-ionic 
polymers to the polycationic polypeptides. 
2. The method of claim 1 wherein the reactive groups 
are selected from the group consisting of hydroxyls, 
carboxyls, diols, aldehydes, amines, and thiols. 
3. The method of claim 1 wherein the non-ionic water 
soluble polymers are selected from the group consisting 
of poly(ethylene oxide), poly(vinyl pyrrolidone), poly 
(ethyl oxazoline), poly(vinyl alcohol) and polysaccha 
rides. 
4. The method of claim 1 wherein the polycationic 
polymers are selected from the group consisting of 
polylysine, polyornithine, polyethyleneimine, and po 
lyallylamine. 
5. The method of claim 1 wherein the sulfonyl chlo 
ride is trifyl chloride. 
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6. The method of claim 1 wherein the sulfonyl chlo- 9. The method of claim 1 wherein the chlorocarbon 
ride is tresyl chloride. ate is p-nitrophenyl chlorocarbonate. 
- 10. The method of claim 1 wherein the chlorocarbon 
7. The method of claim 1 wherein the sulfonyl chlo- ate is 2,4,5 trichlorophenyl chlorocarbonate. 
ride is tosyl chloride. A. 5 11. The method of claim 1 wherein the chlorocarbon 
8. The method of claim 1 wherein the sulfonyl chlo- ate is N-hydroxysuccinamide chlorocarbonate. 
ride is pentafluorobenzenesulfonyl chloride. as sk k g : 
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